<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436941</url>
  </required_header>
  <id_info>
    <org_study_id>53191</org_study_id>
    <nct_id>NCT02436941</nct_id>
  </id_info>
  <brief_title>Radiation Medicine Patient Registry, Loma Linda University Medical Center</brief_title>
  <official_title>Loma Linda University Medical Center Department of Radiation Medicine Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For most cancers, long-term follow-up is the best measure of treatment effectiveness. The
      Department of Radiation Medicine at Loma Linda University Medical Center operates the James
      M. Slater, M.D., Proton Treatment and Research Center, the world's first hospital-based
      proton treatment facility. Patients have been treated at the Center since 1990. Radiation
      treatment has been expanded and refined since the Center's opening, and these changes have
      been based primarily on outcomes seen and evaluated in long-term follow-up.

      The Radiation Medicine Patient Registry (a multi-year database), which began as an
      IRB-approved study in 2003, including detailed follow-up of study data collected from 1990
      and onward, is designed to track all medical information from patients treated with proton
      therapy and/or conventional X-ray therapy at Loma Linda University Medical Center.
      Information gathered from patients treated years or even decades ago helps to determine the
      most effective use of proton and conventional radiation in caring for patients with cancers
      and other diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient registry will be posted to accomplish three objectives:

        1. Perform retrospective research studies on diseases treated with proton therapy and
           conventional photon radiation.

        2. Maintain regular and life-long contact with patients in order to obtain current
           identification, contact information, and self/parent-reported health status. This
           information is used to generate better understanding of treatment strategies and, in
           turn, increase benefits to patients.

        3. Enable physicians to review of medical record information and so to identify subjects
           who may be eligible to participate in future research studies. This requires obtaining
           permission from registered participants that they may be contacted and asked if they are
           interested in participating in studies for which they may be eligible, as determined by
           their medical information contained in the registry.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Anticipated">October 2040</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>99 Years</target_duration>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>One year</time_frame>
    <description>Participants will be followed per protocol pre- during- and following treatment per protocol schedule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>One year</time_frame>
    <description>Participants will be followed per protocol pre- during- and following treatment per protocol schedule</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>One year</time_frame>
    <description>Participants will be followed per protocol pre- during- and following treatment per protocol schedule</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival &amp; Long-term follow-up</measure>
    <time_frame>One year</time_frame>
    <description>Maintaining regular, lifetime contact with patients enables physicians to obtain current identification, contact information, and self/parent-reported health status that can, in turn, generate better understanding of treatment strategies and subsequent benefits to patients</description>
  </other_outcome>
  <enrollment type="Anticipated">75000</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton or Photon</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients who have proton or conventional x-ray therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of benign or malignant tumors or other conditions deemed treatable by proton
             or conventional photon radiotherapy

          -  Willingness to sign an Informed Consent Document

        Exclusion Criteria:

          -  There are no specific exclusion criteria, but patients who are unwilling to sign the
             ICD will not be included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry D Slater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <reference>
    <citation>Slater JD. Development and operation of the Loma Linda University Medical Center proton facility. Technol Cancer Res Treat. 2007 Aug;6(4 Suppl):67-72.</citation>
    <PMID>17668955</PMID>
  </reference>
  <reference>
    <citation>Slater JD. Clinical applications of proton radiation treatment at Loma Linda University: review of a fifteen-year experience. Technol Cancer Res Treat. 2006 Apr;5(2):81-9. Review.</citation>
    <PMID>16551128</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Do S, Lum S, Garberoglio C, Mirshahidi H, Patyal B, Grove R, Slater JD. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):501-5. doi: 10.1016/j.ijrobp.2014.05.1308. Epub 2014 Jul 30.</citation>
    <PMID>25084608</PMID>
  </reference>
  <reference>
    <citation>Slater JM, Ling TC, Slater JD, Yang GY. Palliative radiation therapy for primary gastric melanoma. J Gastrointest Oncol. 2014 Feb;5(1):E22-6. doi: 10.3978/j.issn.2078-6891.2013.057.</citation>
    <PMID>24490048</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, Grove R, Slater JD. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):964-8. doi: 10.1016/j.ijrobp.2013.05.002.</citation>
    <PMID>23845845</PMID>
  </reference>
  <reference>
    <citation>Ling TC, Kang JI, Bush DA, Slater JD, Yang GY. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res. 2012 Dec;24(4):361-7. doi: 10.3978/j.issn.1000-9604.2012.10.09.</citation>
    <PMID>23359779</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Loredo LN, Chung A, Bush DA, Patyal B, Johnson WD, Hsu FP, Slater JM. Fractionated proton radiotherapy for benign cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e633-7. doi: 10.1016/j.ijrobp.2012.01.079.</citation>
    <PMID>22768992</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Slater JD, Garberoglio C, Do S, Lum S, Slater JM. Partial breast irradiation delivered with proton beam: results of a phase II trial. Clin Breast Cancer. 2011 Aug;11(4):241-5. doi: 10.1016/j.clbc.2011.03.023. Epub 2011 Jun 12.</citation>
    <PMID>21729673</PMID>
  </reference>
  <reference>
    <citation>Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1005-9. doi: 10.1016/j.ijrobp.2010.06.047. Epub 2010 Oct 6.</citation>
    <PMID>20932675</PMID>
  </reference>
  <reference>
    <citation>Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010 Mar 17;303(11):1046-53. doi: 10.1001/jama.2010.287. Erratum in: JAMA. 2010 Apr 7;303(13):1257.</citation>
    <PMID>20233822</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011 Jul 1;117(13):3053-9. doi: 10.1002/cncr.25809. Epub 2011 Jan 24.</citation>
    <PMID>21264826</PMID>
  </reference>
  <reference>
    <citation>Slater JM, Slater JD, Wroe A. Proton radiation therapy in the hospital environment: conception, development, and operation of the initial hospital-based facility, Review of Accelerator Science and Technology, Vol 2 (2009), 35-62</citation>
  </reference>
  <reference>
    <citation>Slater JD. Twenty years of proton radiation therapy at Loma Linda University Medical Center. In U. Linz, editor. Ion beam therapy: fundamentals, technology, clinical applications. Berlin: Springer, 2012:581-595.</citation>
  </reference>
  <reference>
    <citation>Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, Grove R, de Vera ME. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):477-82. doi: 10.1016/j.ijrobp.2016.02.027. Epub 2016 Feb 13.</citation>
    <PMID>27084661</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004 Oct;126(4):1198-203.</citation>
    <PMID>15486383</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, Slater JM. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):348-52.</citation>
    <PMID>15145147</PMID>
  </reference>
  <reference>
    <citation>Bush DA, McAllister CJ, Loredo LN, Johnson WD, Slater JM, Slater JD. Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery. 2002 Feb;50(2):270-3; discussion 273-5.</citation>
    <PMID>11844261</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Yonemoto LT, Mantik DW, Bush DA, Preston W, Grove RI, Miller DW, Slater JM. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):494-500.</citation>
    <PMID>15890592</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology. 2004 Nov;127(5 Suppl 1):S189-93.</citation>
    <PMID>15508084</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Slater JD, Bonnet R, Cheek GA, Dunbar RD, Moyers M, Slater JM. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999 Nov;116(5):1313-9.</citation>
    <PMID>10559093</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Rossi CJ Jr, Yonemoto LT, Reyes-Molyneux NJ, Bush DA, Antoine JE, Miller DW, Teichman SL, Slater JM. Conformal proton therapy for early-stage prostate cancer. Urology. 1999 May;53(5):978-84.</citation>
    <PMID>10223493</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Yonemoto LT, Rossi CJ Jr, Reyes-Molyneux NJ, Bush DA, Antoine JE, Loredo LN, Schulte RW, Teichman SL, Slater JM. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299-304.</citation>
    <PMID>9788407</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Jerry D. Slater, MD</investigator_full_name>
    <investigator_title>Chairman &amp; Professor, Department of Radiation Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

